Prognosis of operated hepatocellular carcinoma developed on non-cirrhotic liver

作     者：Morgan Vandermeulen Maxime Dewulf Olivier Detry 

作者机构：Department of Visceral Surgery and TransplantationCHU LiegeLiegeBelgium Centre de Recherche et d’Enseignement du Département de Chirurgie(CREDEC)GIGA MetabolismUniversity of LiegeLiegeBelgium Department of SurgeryMaastricht University Medical Center(MUMC+)MaastrichtThe Netherlands 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2024年第13卷第4期

页      面：736-738页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Cancer surgery transplantation recurrence 

摘      要：The incidence of primary liver cancers,and particularly hepatocellular carcinoma(HCC),is increasing throughout the *** vast majority of HCCs develop on cirrhotic livers(CLs)(CL HCC)or livers chronically infected by hepatotropic viruses,mainly hepatitis B virus(HBV)and hepatitis C virus(HCV)(1).As HCC occurring on non-HBV non-HCV non-CL(NCL)HCC occurs much less frequently,its management is less established than for CL ***,many clinicians might confuse the prognosis and management of NCL HCC with the one of CL *** is however demonstrated that NCL HCCs behave differently than CL *** prognostic factors and sensibility to systemic therapy are different,added to the fact that NCLs can undergo major resections allowing curative surgical management or even systemic therapies that are not even possible in CL HCCs due to the failing function of the *** established criteria for liver transplantation of CL HCCs,including the famous Milan criteria,have no role in NCL HCC management(2-4).The Barcelona Clinic Liver Cancer(BCLC)strategy for prognosis prediction and treatment recommendation also concerns only CL HCCs;and should not be used for NCL HCCs(5).